Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

Improvements in our understanding of the human genome, technological tools like artificial intelligence, and global ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Some providers may need to reduce services, lay off staff or close their doors if Congress enacts major cuts to the ...

Already facing headwinds caused by a patient’s death and treatment delays, the biotech now may have to contend with a less ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

Sales of the company’s copycat to J&J’s blockbuster reached $150 million in the first quarter, adding to a surge in revenue ...

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet ...

Deals with Hims & Hers, LifeMD and Ro follow dismissal of a lawsuit that challenged the FDA's determination Wegovy is no ...